IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 14, 2024 07:00 ET
|
IGM Biosciences, Inc.
– Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 – – Second dose cohort cleared in imvotamab rheumatoid...
IGM Biosciences to Present at the Jefferies Healthcare Conference
May 29, 2024 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 08, 2024 16:10 ET
|
IGM Biosciences, Inc.
- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW,...
IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference
May 07, 2024 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
IGM Biosciences Announces Refocusing of Sanofi Collaboration
April 17, 2024 08:30 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum
April 10, 2024 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 07, 2024 16:10 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension
December 05, 2023 16:01 ET
|
IGM Biosciences, Inc.
– Priorities: clinical development of DR5 agonist in colorectal cancer and T cell engagers in autoimmune disease – – Plans to file IND for IGM-2644 (CD38 x CD3) to treat autoimmune disease – – All...